Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/11199
Title: Biological evaluation of selected 3,4-dihydro-2(1H)-quinoxalinones and 3,4-dihydro-1,4-benzoxazin-2-ones: Molecular docking study
Authors: Petronijević, Jelena
Janković, Nenad
Stanojkovic, Tatjana
Joksimović N.
Grozdanic, Nadja
Vranes, Milan
Tot A.
Bugarčić Z.
Journal: Archiv der Pharmazie
Issue Date: 1-May-2018
Abstract: © 2018 Deutsche Pharmazeutische Gesellschaft In order to investigate new potential therapeutically active agents, we investigated the biological properties of two small libraries of quinoxalinones and 1,4-benzoxazin-2-ones. The results obtained showed that compounds 5, 9–11 have good cytotoxic activity against HeLa cells where the lowest IC50 value (10.46 ± 0.82 μM/mL) was measured for compound 10. Additionally, the most active compounds (5, 9–11) showed much better selectivity for MRC-5 cells (up to 17.4) compared to cisplatin. In vitro evaluation of the inhibition of the enzyme α-glucosidase showed that compounds 10 and 11 exert significant inhibition of the enzyme at 52.54 ± 0.09 and 40.09 ± 0.49 μM, respectively. Competitive experiments with ethidium bromide (EB) indicated that all tested compounds have affinity to displace EB from the EB-DNA complex through intercalation, suggesting good competition with EB (Ksv = (3.1 ± 0.2), (5.1 ± 0.1), (5.6 ± 0.2), and (6.3 ± 0.2) × 103 M−1). A molecular docking study was also performed to better understand the binding modes and to conclude the structure–activity relationships of the synthesized compounds.
URI: https://scidar.kg.ac.rs/handle/123456789/11199
Type: Article
DOI: 10.1002/ardp.201700308
ISSN: 03656233
SCOPUS: 85045481725
Appears in Collections:Faculty of Science, Kragujevac
Institute for Information Technologies, Kragujevac
[ Google Scholar ]

Page views(s)

71

Downloads(s)

1

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.